

# BWH Radiology Documentation

Document Number
7.4.3SOP

Title		
Contrast Administration – Contrast and Renal Insufficiency		
Document Type	Revision Code	Page Number
Standard Operating Procedure	A	1 of 4
PRESUMES PRACTITIONERS KNOWLEDGE OF: (title)	SPECIAL NOTES	
NA	<b>ABSOLUTE CONTRAINDICATIONS: NA</b>  <b>EXPOSURE: NA</b>  <b>PROTECTIVE EQUIPMENT: NA</b>  <b>PATIENT/FAMILY EDUCATION MATERIALS: NA</b>  <b>EQUIPMENT: NA</b>	

## 1.0 PURPOSE

- 1.1 To provide guidelines for determining and responding to Renal Insufficiencies when using Contrast Agents.

## 2.0 SCOPE

NA

## 3.0 RESPONSIBILITIES

NA

## 4.0 DEFINITIONS

NA

## 5.0 POLICY / PROCEDURE

### 5.1 Contrast and Renal Insufficiency:

- 5.1.1 Nephrotoxicity is attributed to radiologic contrast media when there has been a sudden change in renal status after the administration of contrast medium and no other etiology appears likely from the clinical records.
- 5.1.2 Predisposing factors for developing contrast media-induced acute renal failure are pre-existing renal insufficiency (serum creatinine level >1.5 mg/dl), diabetes mellitus, dehydration, cardiovascular disease and the use of diuretics, advanced age (>70 years), myeloma, hypertension, and hyperuricemia although the population at highest risk are patients with both diabetes *and* pre-existing renal insufficiency.

<b>NOTICE</b>		
This document is proprietary and its contents are the exclusive property of Brigham & Women's Hospital. This document may not be reproduced in any form whatsoever, without prior written permission from Brigham & Women's Hospital.		
Refer to 2.1.1SOP for instructions on using this form	Document Number: 7.4.3SOP	REV: A

# BWH Radiology Documentation

Document Number

7.4.3SOP

Title		
Contrast Administration – Contrast and Renal Insufficiency		
Document Type	Revision Code	Page Number
Standard Operating Procedure	A	2 of 4

## 5.2 When to Check Renal Function

5.2.1 For all patients with suspected renal dysfunction or those considered at risk for contrast nephrotoxicity, a baseline serum creatinine level should be obtained before the injection of contrast material.

5.2.2 If any of the following criteria are met a serum creatinine with eGFR must be obtained no less than **3 weeks prior** to the procedure.

5.2.2.1 History of “kidney disease” as an adult, including tumor and transplant

5.2.2.2 Family history of kidney diseases like polycystic kidney disease

5.2.2.3 Diabetes treated with insulin or other prescribed hypoglycemic medications

5.2.2.4 Myeloma or other Paraproteinemia syndromes or diseases

5.2.2.5 Lupus and other Collagen vascular diseases

5.2.2.6 Metformin or metformin-containing drug combinations

## 5.3 Certain medications: *Require Creatinine Measurements within 24 hours prior to the procedure.*

5.3.1 Nonsteroidal anti-inflammatory drugs (Cox-1 and Cox-2 Inhibitors) - **if used for 4 consecutive days** with the last dose **within 24 hours of the procedure** (comprehensive list on file)

5.3.2 Recent and multiple intravenous doses ( 2 or more days of therapy) of the nephrotoxic antibiotics amikacin, gentamicin, tobramycin, and vancomycin if last dose given **within 7 days of the procedure**

5.3.3 Recent and multiple intravenous doses ( 2 or more days of therapy) of the antifungal drug Amphotericin B ( not including Ambisome) if last dose given **within 7 days of the procedure**

5.3.4 Nephrotoxic chemotherapeutic drugs;

5.3.4.1 Methotrexate given **within 3 days of procedure**

5.3.4.2 Cisplatin given within 3 weeks of procedure

5.3.4.3 Previous contrast enhanced study within 48 hours

### NOTICE

This document is proprietary and its contents are the exclusive property of Brigham & Women's Hospital. This document may not be reproduced in any form whatsoever, without prior written permission from Brigham & Women's Hospital.

# BWH Radiology Documentation

Document Number

7.4.3SOP

Title

Contrast Administration – Contrast and Renal Insufficiency

Document Type

Revision Code

Page Number

Standard Operating Procedure

A

3 of 4

**5.4** If renal insufficiency is identified, the referring clinician should be advised regarding alternative imaging approaches. Other precautionary recommendations are to increase the interval between contrast media examinations, to reduce the contrast dose, and hydrate the patient.

**5.5** Other patients who are scheduled for a routine intravascular study do *not* necessarily need a serum creatinine determination before the examination.

## **5.6 HOW TO CHECK RENAL FUNCTION**

5.6.1 Serum creatinine has definite limitations as an accurate measure of renal function because it is influenced greatly by the patient's gender, muscle mass, nutritional status, and age. Normal serum creatinine levels are maintained until the glomerular filtration rate (at least as reflected in creatinine clearance) is reduced to nearly 50%; that is, impaired renal function may exist even when serum creatinine levels are "normal".

## **5.7 SERUM CREATININE AND VOLUME OF CONTRAST**

5.7.1 Renal function is assessed on the basis of serum creatinine (SCr) and estimated glomerular filtration rates (eGFR), which should be estimated using the MDRD equation:

$$5.7.1.1 \text{ eGFR (mL/min/1.73 m}^2\text{)} = 175 \times (\text{Scr})^{-1.154} \times (\text{Age})^{-0.203} \times (0.742 \text{ if female})$$

*Footnote: If patient is black, multiply by 1.21*

5.7.2 When eGFR is less than 60 ml/min (in a normal adult) the term "renal insufficiency" has been used, and when eGFR is less than 30 ml/min the term "renal failure" is often used.

## **5.8 The contrast dose should be adjusted if:**

5.8.1 eGFR is between 30-60 ml/min ® reduce the dose by at least 25% recommended

5.8.2 eGFR less 30 ml/min do not inject unless **(a)** patient is on dialysis (the schedule for dialysis does not need to be changed); **(b)**the study is a medical necessity (risks and benefits should be discussed by physicians).

**5.9** Documentation of this discussion should be entered into the comments section of the Percipio protocoling portal which will be copied into the finalized report.

### **NOTICE**

This document is proprietary and its contents are the exclusive property of Brigham & Women's Hospital. This document may not be reproduced in any form whatsoever, without prior written permission from Brigham & Women's Hospital.

